Long-term administration of low-dose phosphodiesterase type 5 inhibitors for erectile dysfunction: an update.
- Author:
Rui JIANG
1
Author Information
1. Department of Urology, The Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, China. jiangrui@126.com
- Publication Type:Journal Article
- MeSH:
Erectile Dysfunction;
drug therapy;
Humans;
Male;
Phosphodiesterase 5 Inhibitors;
administration & dosage;
therapeutic use;
Treatment Outcome
- From:
National Journal of Andrology
2013;19(3):195-198
- CountryChina
- Language:Chinese
-
Abstract:
Erectile dysfunction (ED) is a common disorder that affects the quality of life of both men and their partners. The phosphodiesterase type 5 inhibitor is the first-line drug for ED. Recent researches found that long-term administration of low-dose phosphodiesterase type 5 inhibitors to be a safe and effective therapy for ED, as well as for couples who may prefer more convenience and spontaneity in their sexual activities. Besides, it provides a new therapeutic option for refractory ED. Its action mechanism mainly involves the improvement of the endothelial function of penile vessels and/or maintenance of the function and number of smooth muscle cells. However, whether this therapy can maintain the improved erection function after drug withdrawal needs further studies.
